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EDITORIAL 
EQUIVALENCE AND NON-INFERIORITY TRIALS IN A SNAPSHOT 
Salima Kerai 
Department of Paediatrics, Aga Khan University, Karachi-Pakistan 
Randomized controlled trials conventionally entails superiority hypothesis where researcher is 
interested to know whether a new treatment is better than the standard of care. However, 
developing and testing novel techniques or therapies which are better than standard is not always 
feasible.  There are circumstances when effective treatment exists and new treatment is not 
substantially better than existing treatment and conducting placebo controlled trials are unethical. 
Then goal of the investigator changes; if new treatment is equivalent or non-inferior in comparison 
to current standard of care with respect to a-priori set endpoints. The current paper aims to discuss 
few key principles of equivalence and non-inferiority trial design and some challenges to think 
about before designing or conducting these trials.  
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Generally, when we think of a trial hypothesis of 
interest, we think of superiority hypothesis whereby the 
investigator intends to determine that a new 
(experimental) treatment is better than the control 
treatment (standard or placebo). In superiority trials 
researcher claims that a new treatment is different (two 
sided) or better (one sided) than the control arm and the 
null hypothesis is that there is no difference between the 
treatment arms. These trials are useful in testing new 
therapies (preventive, therapeutic or rehabilitative) in 
order to establish a standard of care or test therapies 
which are better than the standards in place. 
Sometimes developing novel techniques or 
therapies which are better than the standard of care are 
more difficult or treatment effect differs no more than a 
specific amount. Then goal of the investigator changes; 
if the new treatment is equally safe as thecurrent 
standard of care. For this type of question, equivalence 
design is the most suited where the researcher’s 
hypothesis is that difference between two treatments is 
equal to predefined ‘x’ which is called equivalence 
margin. In other words, researcher tends to prove that 
new treatment is no better or no worse than standard of 
care as far as difference between two treatments is 
within equivalence margin.  
In a multicentre randomized controlled trial at 
district level in Uganda, investigators claimed that the 
safety and effectiveness of diagnosing and treatment of 
incomplete abortion with misoprostol was equivalent 
between midwives and physicians.2 They randomly 
allocated women with first-trimester incomplete 
abortion to clinical assessment and treatment with 
misoprostol either by a physician or a midwife. The 
Primary outcome was complete abortion not needing 
surgical intervention within 14–28 days after initial 
treatment with predefined equivalence of -4% to 4%. 
The estimated risk difference for midwives versus 
physicians group was -0.8% (95% CI -2.9 to 1.4) which 
was falling within equivalence margin proving abortion 
with misoprostol by midwives is equally safe and 
effective when provided by physicians. 
Besides, equivalence design requires a larger 
sample size in order to rule out large differences and to 
have a high probability of detecting a difference within a 
margin. In equivalence designs researchers’ hypothesis 
are revered as compared to superiority hypothesis. For 
the equivalence design null hypothesis is that there is a 
difference between two groups and researcher claims 
that there is no difference or difference is within the 
equivalence margin (two sided). Correspondingly, type I 
and type II errors are also flipped. In equivalence design 
type I error is failure to reject the null when difference 
exists and type II error is wrongly rejecting null when 
there is no difference.   
However, situations arise where 
investigators are unable to accept claims of 
equivalence. There are circumstances when effective 
treatment exists and new treatment is not 
substantially better than existing treatment and 
conducting placebo controlled trials are unethical. 
This issue can be addressed by non-inferiority 
hypothesis where investigator claims that new 
treatment is ‘no worse’ than existing treatment by 
more than a pre-specified amount which is called 
non-inferiority (NI) margin.  
Similar to equivalence trials, we are detecting 
small differences in non-inferiority trials with reversed 
hypothesis and type I and type II errors. While 
hypothesis of non-inferiority trials are one sided as 
compared to equivalence hypothesis which are two 
sided. Therefore, lesser sample size is required in non-
inferiority trials to reject the null.  Because essentially in 
non-inferiority trials, we are showing that new 
treatment’s response if worse, still sufficiently close to 
the established treatment response, so that new 
treatment is as good as or not worse than the established 
treatment. 
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Non-inferiority trials offer other advantages in 
experimenting therapies for endpoints like better safety 
profile or lower cost or ease of administration or 
compliance which are important from a clinical point of 
view. For example, in case of childhood pneumonia, 
amoxicillin is standard of care. Testing any new drug 
against placebo would be unethical in presence 
amoxicillin. In such case, the investigator can aim to test 
non-inferiority of new drug in comparison to 
amoxicillin using lower cost or safety as clinical 
endpoints.   
In an undergoing double blind randomized 
controlled trial in Karachi, Pakistan, investigators 
claimed that ‘no treatment’ (3 days of placebo) is non-
inferior to ‘treatment’ (3 days of amoxicillin-WHO 
standard of treatment) in management of children with 
WHO defined fast breathing pneumonia.1 Children 2–59 
months of age with fast breathing, without any danger 
sign are randomly allocated to receive either three days 
of placebo or amoxicillin. Primary outcome is the 
difference in cumulative treatment failure between the 
two groups with a non-inferiority margin of 2.5%. For 
analysis of non-inferiority trials, researchers need to get 
a confidence interval (CI) for difference between two 
arms and note that lower or upper bound of the CI does 
not exceed NI margin (in predefined direction). There 
are times when the new treatment is statistically better 
than the control arm where CI is entirely above or below 
zero showing superiority. In such cases, investigators 
need to plan in advance that if non-inferiority is 
established then they can test for superiority.  
The important thing is to carefully choose 
equivalence and non-inferiority margin, which is based 
on clinical and statistical significance and prior research 
experience. It should be carefully decided before 
commencing the trial as it gives scientific credibility to 
the trial. Equivalence and non-inferiority margin is the 
minimum difference investigator can tolerate with 
respect to specified endpoints in given direction. In 
order to avoid type I error (false claim of equivalence or 
non-inferiority when outcome is actually equivalent or 
inferior), it is important to avoid margin that is too large 
and  has potential to adversely affect the participants. In 
addition, the sample size must be sufficient enough on 
the carefully selected margin, alpha and power to 
declare equivalence and non-inferiority. Of note, 
conservative margins require more sample size to detect 
differences.  
In contrast to intention to treat analysis, 
equivalence and non-inferiority trials conventionally 
incorporate per-protocol analysis. Intention to treat 
analysis includes participants who were initially 
randomized to treatment assignment whether they 
adhere to the group or not or were lost to follow-up. It 
has potential to bias results towards null if there is lots 
of crossover among treatment groups. Per protocol 
analysis on the other hand includes participants who 
adheres to specific treatment group and excludes 
protocol deviation and violations. However, excluding 
these data points may also bias results in either 
direction, particularly in survival trials where one might 
discontinue study drug due to other fatal condition. It is 
therefore advised to analyse equivalence and non-
inferiority trials by using both approaches. Moreover, 
control arm must have a standard of care, otherwise, it 
would be unethical if the comparator is less optimal 
choice of treatment.  
Quality of trial depends upon what endpoint is 
chosen and how it is measured and how many lost to 
follow-ups are there. In order to ensure validity of 
outcome estimate, quality control measures need to be 
in place to ensure adherence to standard operating 
procedures, to minimize protocol deviations and 
violations and minimize lost to follow-up. It should be 
clearly stated how missing data would be handled if any 
present and method used to deal with missing data. 
Moreover, sensitivity analysis must be carried out to 
ensure robustness of primary outcome with and without 
missing data values. Specifically, in non-inferiority 
trials, there should be consistency between type I error 
rate and confidence interval margin. And hypothesis is 
one sided based on one sided alpha which is 
conventionally taken as 5% . Correspondingly, one 
sided 95% CI or two sided 90% CI should be calculated. 
The p-values are generally not required and if P value is 
calculated, then it should be reported for one sided test 
only.   
Correct understanding of trial design is pre-
requisite for conducting and interpreting trials with valid 
outcomes and to answer the research question in an 
appropriate way.  
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